Seeking Alpha

Seeking Alpha Portfolio App for iPad

429 people get SLXP articles and Market Currents by email alert.

Get email alerts on SLXP »

SLXP

Salix Pharmaceuticals, Ltd.

5/25/2013, 10:53 AM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Friday, May 10, 8:58 AM More on Progenics' (PGNX) earnings: Relistor sales rise 47% Q/Q and fall 37% Y/Y, as royalties were $1.2M in Q1 compared to $1.8M in Q1 2012. Data from Salix (SLXP) (which said on its CC that prescription growth increased 52% Y/Y) including the regional breakdown, shows Relistor net sales of $6.7M in the U.S. and $1M outside the country. SLXP also notes that it believes a path forward for the drug (in terms of expanding its indications) "could be reached with the FDA" this year. PGNX shares +21% premarket. (PR) Comment! [Healthcare, On the Move]
Monday, December 31, 2012, 3:37 PM Salix Pharmaceutical's (SLXP +1.4%) moves up after the FDA approves Fulyzaq to relieve symptoms of diarrhea in HIV/AIDS patients taking antiretroviral therapy. The drug, which is the first of its kind to relieve diarrhea in AIDS patients and is a common reason why patients discontinue or switch their antiretroviral therapies, is distributed by SLXP under license from Napo Pharmaceuticals. Comment! [Healthcare, On the Move]
Thursday, November 8, 2012, 3:42 PM Salix Pharmaceuticals (SLXP +7.5%) gets a pop today after its Q3 EPS came in well ahead of expectations and the drug developer raised its FY12 profit guidance for the third time this year. Sales of its key antibiotic drug Xifaxan jumped 43%, leaving analysts estimates in the dust. The company now expects an FY12 EPS of $3.13 on revenues of $735M, above the Street estimate of $2.89 on revenues of $739M. Comment! [Healthcare, Earnings, On the Move]
Wednesday, November 7, 2012, 4:41 PM Salix Pharmaceuticals (SLXP): Q3 EPS of $0.95 beats by $0.25. Revenue of $185.1M (+26.6% Y/Y) misses by $2M. Shares +8.4% AH. (PR) Comment! [Earnings, Healthcare, On the Move]
Thursday, August 9, 2012, 1:35 PM Salix Pharmaceuticals (SLXP +2%) trades higher after beating bottom line Q2 estimates yesterday. Net profit rose 4.6% as the drug developer saw continued strength in sales of its Xifaxan tablets. The company also raised its FY12 outlook to $2.86 per share, up from its previous view of $2.59 a share, reflecting its March placement of $690M in senior notes. Comment! [Healthcare, Earnings, On the Move]
Wednesday, August 8, 2012, 5:28 PM Salix Pharmaceuticals (SLXP): Q2 EPS of $0.79 beats by $0.25. Revenue of $181M (+36% Y/Y) in-line. Shares +9.4% AH. (PR) Comment! [Earnings, Healthcare, On the Move]
Monday, July 30, 2012, 9:10 AM Premarket gainers: SHAW +65%. CDTI +60%. VRML +14%. ATPG +11%. OCZ +11%. BBY +8%. EXEL +5%. ACI +5%. MDR +5%.
Losers: PGNX -44%. SLXP -12%. STP -11%. CBI -10%. Comment! [On the Move]
Monday, July 30, 2012, 8:57 AM Salix Pharmaceuticals (SLXP) -10.7% and Progenics Pharmaceuticals (PGNX) -47% after saying late on Friday that the FDA has asked for more data on their Relistor drug for patients who have become constipated from taking opioids to treat chronic non-cancer pain. Comment! [Healthcare, On the Move]
Tuesday, April 10, 2012, 11:20 AM Salix Pharmaceuticals (SLXP -4.8%) slides after Auriga downgrades the stock to Hold from Buy and lowers its price target to $51 from $54. The firm says SLXP shares appear to have already priced in upside from the potential approval of developmental drugs Relistor and Crofelemer. Auriga had upgraded shares to Buy only six weeks ago. Comment! [Healthcare, On the Move]
Tuesday, February 28, 2012, 12:24 PM Salix Pharmaceuticals (SLXP +7.1%) spikes higher on volume 3X normal trading activity after Auriga upgrades it to a Buy rating with a $54 price target. Analysts call the firm's 2012 guidance conservative and indicate that they see a high likelihood that Salix will outperform. Comment! [Healthcare, On the Move]
Tuesday, February 28, 2012, 11:49 AM Salix Pharmaceuticals (SLXP +7.3%) shares surge after Q4 results topped expectations and sales of its Xifaxan gastrointestinal drug picked up significantly during H2 2011. SLXP also guides to at least 25% organic growth in Xifaxan in 2012, with strong growth in January that beat the prior record month of December. Comment! [Healthcare, On the Move]
Friday, February 10, 2012, 11:02 AM Salix Pharmaceuticals (SLXP -7.7%) plunges after the FDA provides relatively lenient clinical study guidelines (.pdf) for would-be makers of a generic version of Salix's Xifaxan drug. Salix closed yesterday near its 52-week high. Comment! [Healthcare, On the Move]
Tuesday, December 20, 2011, 9:05 AM Premarket gainers: CSIQ +27%. PGNX +26%. AIS +17%. SLXP +11%. S +7%. CLWR +7%. JEF +6%. ALU +6%. NOK +5%. DB +5%. RIO +5%. MT +4%. STD +4%. BBVA +4%. STM +4%. VHC +4%. GSS +4%. ANR +4%. MS +4%. ERIC +4%. BHP +3%. ZMH +3%. VALE +3%. ITUB +3%. SNE +3%. C +3%. VE +3%. X +3%. MU +3%. HAL +3%. SI +3%.
Losers: TRGT -22%. RHT -8%. GFA -4%. Comment! [On the Move]
Tuesday, December 20, 2011, 8:45 AM Salix Pharmaceuticals (SLXP) and Progenics (PGNX) report "positive" highly statistically significant results of the Phase 3 of oral methylnaltrexone for the treatment of opioid-induced constipation in subjects with chronic, non-cancer pain. SLXP +11%, PGNX +18.8% premarket. (PR) Comment! [Healthcare, On the Move]
Wednesday, December 14, 2011, 12:19 PM Salix Pharmaceuticals (SLXP +0.2%) says it's submitted a New Drug Application to the FDA for its HIV-induced diarrhea drug Crofelemer. The agency has 60 days to review the application and decide whether it will enter its review process. The drug developer is also researching alternative possible uses for the drug, including the treatment of irritable bowel syndrome. Comment! [Healthcare, On the Move]
Thursday, November 17, 2011, 9:29 AM Salix Pharmaceuticals (SLXP) +8.4% premarket after saying that an FDA advisory panel supports its proposed trial to test repeat treatment cycles of its Xifaxan tablets for irritable bowel syndrome. (earlier) Comment! [Healthcare, On the Move]